Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-ACS: Milvexian After Recent Acute Coronary Syndrome
jRCT2031230100Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) comparing Milvexian + standard antiplatelet therapy with Placebo + standard antiplatelet therapy (2 arms). Primary endpoint: Time to First Occurrence of Major Adverse Cardiovascular Event (MACE). Started Jul 2023; status: completed.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on jRCT2031230100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230100.